01.002 RWE KR JULY 2022 H 5-8-22

Real-world evidence (RWE) market worth over £1bn by 2023

  • Oncology segment accounted for the largest share of the RWE solutions market in 2017
  • The rising focus on end-to-end RWE services and growth within emerging markets are expected to provide further business opportunities for players operating in the RWE market
Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.


DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.

For more information, please visit and contact us at